Vivus Inc. (VVUS) said that the FDA advisory committee has voted against the approval of Qnexa for the treatment of obesity.
The FDA will take the committee's recommendation into consideration during its review of the current application and will make a determination. The FDA is expected to make a final decision on Qnexa by October 28, 2010.
In clinical studies, Qnexa has shown to reduce body weight by 10% to 15% over a year, besides improving cardiovascular and other obesity-related risk factors and even reducing sleep apnea (sleep disorder).
The FDA benchmark requires only at least a 5% weight loss in one third of study group.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.